Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: GOOG NFLX BIIB IBB AMZN TSLA ALXN ILMN WYNN AMGN GMCR SLXP COST GILD AAPL CELG WDC SNDK INTU
Nyse: ACT V MCK LNKD IVV AGN LMT GS PXD SPG FDX IBM MMM CMI TWC GD NOC APD BDX PH
New Highs: IBB V ILMN ALXN LMT ORLY WHR AMGN MMM GMCR GD NOC HUM COST BXP EW SLG SBAC GILD SRE

The Hot Industries

Biotechnology 4
Aerospace/Defense Products & Services 2
Medical Appliances & Equipment 1

The Hot Sectors

Healthcare 6
Industrial Goods 4
Financial 3

ARIA Stock Chart


ARIA
Analyze

Sector:

Healthcare
Daily

Industry:

Biotechnology
Weekly

Employees:

307
Monthly

Website:

http://www.ariad.com

ARIA Ariad Pharmaceuticals Inc.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing additional molecularly targeted therapies to treat patients with blood cancers and solid tumors. Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia, who are resistant or intolerant to prior TKI therapy, as well as for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to prior TKI therapy. Its product pipeline consists of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers; and AP1903, a small-molecule dimerizer drug. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus, for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

favicon

MGM Resorts International Reports Third Quarter Financial Results

30 Oct 2014, 6:00 amLAS VEGAS, Oct. 30, 2014 /PRNewswire/ -- MGM Resorts International (NYSE: MGM) today reported financial results for the quarter ended September 30, 2014.  Diluted loss per share for the third quarter of ...
favicon

Restaurant review: Woodfire Grill

29 Oct 2014, 2:12 amInconsistent service distracts from good food and drink by Jennifer Zyman Woodfire Grill owner Nicolas Quinones says he considers his restaurant one of Atlanta's top four fine dining establishments along with Aria, Restaurant Eugene, and Bacchanalia. He says he believes in the beauty of fine dining as an art form, from the crisp white linens to a server's posture while approaching a table to the ...
favicon

Commit To Buy ARIAD Pharmaceuticals At $3.50, Earn 17.1% Using Options

27 Oct 2014, 10:12 amInvestors considering a purchase of ARIAD Pharmaceuticals, Inc. (NASD: ARIA) shares, but cautious about paying the going market price of $5.63/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2016 put at the $3.50 strike, which has a bid at the time of this writing of 60 cents ...
favicon

Ariad Pharma: Will It Return To Its Heyday?

27 Oct 2014, 7:50 amShares of Ariad Pharmaceuticals Inc. (ARIA) have gained more than 60 percent in the last one year, and it looks like the company is slowly getting back in the game. Here's the story of the fall and recovery of Ariad...
favicon

Why Ariad Pharmaceuticals, Inc. Stock Catapulted Higher

26 Oct 2014, 8:46 amAriad Pharmaceuticals stock is among today's top gainers after the Food and Drug Administration divvies a prized designation one of Ariad's pipeline products.
favicon

Amgen's Blinatumomab Gets Priority Review in the U.S. - Analyst Blog

13 Oct 2014, 5:31 pmInvestors in the pharma biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give
favicon

ARIAD Gets Breakthrough Therapy Designation for AP26113 - Analyst Blog

6 Oct 2014, 5:30 pmARIAD Gets Breakthrough Therapy Designation for AP26113 - Analyst Blog
favicon

ARIAD Gets Breakthrough Therapy Designation for AP26113

6 Oct 2014, 2:55 pmAriad Pharmaceuticals Inc. (ARIA) announced that the FDA has granted Breakthrough Therapy designation to its lung cancer candiadate, AP26113 for the treatment of ALK+ non-small cell lung cancer (NSCLC)....
favicon

Why Ariad Pharmaceuticals (ARIA) Stock Is Spiking Today

2 Oct 2014, 9:59 amNEW YORK (TheStreet) -- Ariad Pharmaceuticals shares are up 8.6% to $5.74 on Thursday after the company announced that its experimental lung cancer drug received a "breakthrough therapy" designation from the FDA. A "breakthrough therapy designation" means that the FDA can fast track the review process for aadrug that shows evidence of being an improvement of current treatments for patients with ...
favicon

Bulls Target Ariad Pharmaceuticals, Inc. (ARIA) Amid Drug News

2 Oct 2014, 9:44 amAriad Pharmaceuticals, Inc. (NASDAQ:ARIA) gapped higher this morning on news that its lung cancer drug, ... ( Read More )